American Cancer Society; American Legacy Foundation; Elan Pharmaceutical; Free and Clear; GlaxoSmithKline; Group Health Cooperative; National Institutes of Health; North American Quit Line Consortium; Pfizer International; Robert Wood Johnson Foundation; Roswell Park Cancer Institute; Sanofi; United States Department of Health and Human Services; United States Centers for Disease Control and Prevention; University of Wisconsin
Persons Mentioned
Burns, David Michael, M.D.; Carmona, Richard H.; Davis, Ronald Mark, M.D.; Delano, Richard; Healton, Cheryl G.; Koh, Howard K.; McAfee, Dr.; Reed, Robert M., D.D.S.; Reister, Tim; Shelton, Dana; Zhu, Shu Hong
Description
The plaintiff's expert witness, an expert in smoking cessation, continued to testify. He explained how he arrived at his estimates of how many smokers would use a National Quit Line and how many would be successful in quitting. He described how the Group Health Cooperative’s Free and Clear program use these figures in establishing a cost model that estimated the costs associated with implementing a national comprehensive Quit Line. He discussed the methodology that was used to arrive at the estimate of a one billion dollar cost for a national advertising campaign. He reviewed the costs associated with supplying smokers with nicotine gum. The witness discussed studies that have been done of the cost effectiveness of current quit lines and cessation programs. He explained why it is so important to eliminate the barriers that hamper these programs. He indicated that when people are given access to a well-integrated, systematized comprehensive resource that utilization rates go up.
Case Name
United States of America v. Philip Morris U.S.A. Inc.
Date Added UCSF
20071206 (December 6, 2007)
Witness
Fiore, Michael C., M.D., M.P.H. (affiliation: University of Wisconsin Department of Medicine; expertise: Nicotine Addiction; job_title: Director of Tobacco Research and Intervention Program; side: Plaintiff; witness_type: Expert)